& Events
& Events
News
& Events
Sep 15, 2022 Inversago Pharma receives IND clearance for Phase 2 trial of INV-202 in Diabetic Kidney Disease
– FDA clears IND of First-In-Class, Peripherally-Acting CB1 Inverse Agonist INV-202 – Phase 2 trial in Diabetic Kidney Disease will also provide data in complications of diabetes, metabolic syndrome and dyslipidemia MONTREAL (CANADA) – September 15, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse […]
Sep 5, 2022 Inversago Pharma presents data on INV-101 in Idiopathic Pulmonary Fibrosis at the ERS Congress 2022
MONTREAL (CANADA) – September 5, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 2022 Congress of the European Respiratory Society (ERS), currently held in Barcelona, Spain and online. These data show that Inversago’s INV-101 (zevaquenabant), a […]
Aug 18, 2022 Inversago Pharma to present preclinical data on INV-101 in Idiopathic Pulmonary Fibrosis at the ERS Congress 2022
MONTREAL (CANADA) – August 18, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 2022 Congress of the European Respiratory Society (ERS), to be held in Barcelona, Spain and online. Abstract: “INV-101, a cannabinoid receptor-1 inverse agonist, […]
Jun 9, 2022 Inversago Pharma to participate to BIO International Convention 2022 in San Diego, CA
MONTREAL (CANADA) – June 09, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announces that the company will be present at the upcoming BIO International Convention to be held in San Diego, CA June 13-16, 2022. – François Ravenelle, PhD, Chief Executive Officer […]
